A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

This multicenter, open-label, randomized phase 2 study evaluated 2 dose regimens of lenalidomide for relapsed, refractory myeloma. Seventy patients were randomized to receive either 30 mg once-daily or 15 mg twice-daily oral lenalidomide for 21 days of every 28-day cycle. Patients with progressive o...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Richardson, Paul G., Blood, Emily, Mitsiades, Constantine S., Jagannath, Sundar, Zeldenrust, Steven R., Alsina, Melissa, Schlossman, Robert L., Rajkumar, S. Vincent, Desikan, K. Raman, Hideshima, Teru, Munshi, Nikhil C., Kelly-Colson, Kathleen, Doss, Deborah, McKenney, Mary L., Gorelik, Svetlana, Warren, Diane, Freeman, Andrea, Rich, Rebecca, Wu, Anfang, Olesnyckyj, Marta, Wride, Kenton, Dalton, William S., Zeldis, Jerome, Knight, Robert, Weller, Edie, Anderson, Kenneth C.
Format: Artigo
Jezik:Inglês
Izdano: © 2006 by The American Society of Hematology 2006
Teme:
Neoplasia
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895441/
https://ncbi.nlm.nih.gov/pubmed/16840727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-04-015909
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items